Thromboprophylaxis in lower limb immobilisation after injury (TiLLI)

Emerg Med J. 2020 Jan;37(1):36-41. doi: 10.1136/emermed-2019-208944. Epub 2019 Nov 6.

Abstract

Venous thromboembolic disease is a major global cause of morbidity and mortality. An estimated 10 million episodes are diagnosed yearly; over half of these episodes are provoked by hospital admission/procedures and result in significant loss of disability adjusted life years. Temporary lower limb immobilisation after injury is a significant contributor to the overall burden of venous thromboembolism (VTE). Existing evidence suggests that pharmacological prophylaxis could reduce overall VTE event rates in these patients, but the proportional reduction of symptomatic events remains unclear. Recent studies have used different pharmacological agents, dosing regimens and outcome measures. Consequently, there is wide variation in thromboprophylaxis strategies, and international guidelines continue to offer conflicting advice for clinicians. In this review, we provide a summary of recent evidence assessing both the clinical and cost effectiveness of thromboprophylaxis in patients with temporary immobilisation after injury. We also examine the evidence supporting stratified thromboprophylaxis and the validity of widely used risk assessment methods.

Keywords: cost effectiveness; musculo-skeletal, fractures and dislocations; pulmonary embolism; risk management; thrombo-embolic disease.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use*
  • Clinical Decision-Making
  • Cost-Benefit Analysis
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Immobilization* / adverse effects
  • Leg Injuries / blood
  • Leg Injuries / physiopathology*
  • Leg Injuries / therapy
  • Practice Guidelines as Topic
  • Risk Assessment
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / prevention & control*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight